Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Vasc Interv Radiol. 2016 Dec 9;28(2):231–237.e2. doi: 10.1016/j.jvir.2016.09.022

Figure 4.

Figure 4

A sensitivity analysis was performed limiting the TACE patients to those who were treated within 90 days after the HCC diagnosis date in effort to minimize the immortal time bias. Overall survival remained significantly improved in HCC patients treated with TACE within 90 days of diagnosis compared to patients not treated with TACE (median survival: 9.5 months-TACE within 90 days vs. 3.6 months-no treatment, p<0.0001).